AstraZeneca (LON:AZN) had its price target lifted by Barclays from GBX 6,800 ($88.85) to GBX 7,000 ($91.47) in a research note issued to investors on Monday, April 1st, ThisIsMoney.Co.Uk reports. They currently have an overweight rating on the biopharmaceutical company’s stock.
Other research analysts have also recently issued reports about the stock. Deutsche Bank reissued a buy rating and set a GBX 6,900 ($90.16) price target on shares of AstraZeneca in a report on Monday, February 18th. Bryan, Garnier & Co cut shares of AstraZeneca to a neutral rating in a report on Friday, February 22nd. JPMorgan Chase & Co. set a GBX 6,900 ($90.16) target price on shares of AstraZeneca and gave the company a buy rating in a report on Tuesday, January 1st. Shore Capital reaffirmed a hold rating on shares of AstraZeneca in a report on Friday, December 7th. Finally, Liberum Capital reaffirmed a hold rating on shares of AstraZeneca in a report on Thursday, February 14th. Three analysts have rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the stock. AstraZeneca currently has an average rating of Hold and an average target price of GBX 6,362.70 ($83.14).
Shares of AstraZeneca stock traded down GBX 7 ($0.09) during trading hours on Monday, reaching GBX 5,908 ($77.20). 1,886,412 shares of the company were exchanged, compared to its average volume of 2,310,000. AstraZeneca has a 1 year low of GBX 4,928.50 ($64.40) and a 1 year high of GBX 6,540 ($85.46). The firm has a market capitalization of $77.50 billion and a P/E ratio of 34.75. The company has a current ratio of 0.96, a quick ratio of 0.71 and a debt-to-equity ratio of 136.31.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Read More: Growth Stocks
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.